A Phase 2 interventional study of olaparib and paclitaxel in Gastric Cancer, sponsored by AstraZeneca. Completed at 7 sites in Korea, Republic of. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2023-07-20.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Stomach Neoplasms by AstraZeneca — 10 open to participants now, 18 under way, 3 of them phase 3. Stomach Neoplasms · AstraZeneca.
Among the 30 studies in Stomach Neoplasms by AstraZeneca, this one is the 14th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2010, is one of 9 in phase 2, and was the 3rd registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.
Browse Stomach Neoplasms studies →10 of the 30 studies in Stomach Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Greece
Ages 18–130
AstraZeneca · Sites in United States, Australia, Austria and 21 more countries
Ages 18+
AstraZeneca · Sites in United States, Australia, Japan and 1 more country
Ages 18+
AstraZeneca · Sites in United States, Canada, China and 8 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 25 more countries
Ages 18+
By country, each count listing its studies:
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 16 · Phase 3 4
First in 2007; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 124 is above the median of 66 across 2,502 interventional studies indexed under Stomach Neoplasms.
Median enrollment 124 across the 27 interventional studies, 300 across the 3 observational. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
8 of the studies in Stomach Neoplasms by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06219941AstraZenecaAZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | 2026-11-17 |
| NCT06147037AstraZenecaA Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | 2026-12-31 |
| NCT06921928AstraZenecaStudy for AZD4360 in Participants With Advanced Solid Tumours | 2027-03-31 |
| NCT04379596AstraZenecaPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | 2027-05-04 |
| NCT04644068AstraZenecaStudy of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | 2027-05-28 |
Add all 8 to your calendar (.ics) → With an account.
Among the 30 studies in Stomach Neoplasms by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess the efficacy of olaparib when given in combination with paclitaxel compared with paclitaxel alone as defined by progression-free survival (PFS), in all patients with recurrent and metastatic gastric cancer who progress following first-line therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Olaparib + paclitaxel
Drug: olaparib · Drug: paclitaxel
paclitaxel + placebo
Drug: paclitaxel · Drug: Placebo
100mg BID oral tablet continuous
iv infusion 80mg/m2 on Day 1, 8 and 15 of a 28 day cycle
Also known as: Taxol
100mg BID oral tablet to match olaparib tablet
Progression Free Survival (PFS) in the Overall Study Population
PFS is defined as the time from randomisation till objective progression or death. In absence of progression or death, the time is calculated from randomisation till last evaluable scanning visit.
Time frame: Tumour assessments were carried out at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed maximum up to 27 months
Progression Free Survival (PFS) in Patients With Tumours Defined as Homologous Recombination Deficient by Loss of Ataxia-Telangiectasia Mutation (ATM) Protein [ATM Negative Patients]
PFS is defined as the time from randomisation till objective progression or death. In absence of progression or death, the time is calculated from randomisation till last evaluable scanning visit.
Time frame: Tumour assessments are carried out at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed maximum up to 27 months
Overall Survival (OS) in the Overall Study Population
Overall survival is defined as the duration from randomisation till death. In absence of death, the time is calculated from randomisation till the date subject last known to be alive.
Time frame: Survival follow up from randomisation till death of the patient or till end of study in absence of death, assessed maximum up to 27 months
Overall Survival (OS) in ATM Negative Patients
Overall survival is defined as the duration from randomisation till death. In absence of death, the time is calculated from randomisation till the date subject last known to be alive.
Time frame: Survival follow up from randomisation till death of the patient or till end of study in absence of death, assessed maximum up to 27 months
Objective Response Rate (ORR) in the Overall Study Population
Objective response rate is the proportion of patients with at least one measurable lesion at baseline, who experienced complete or partial response at least once during the assessment period, according to the definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1).
Time frame: Tumour assessments carried out at baseline, 28 days before randomisation then every 8 weeks until week 40, after week 40 assessments will be carried out every 16 weeks until objective disease progression, assessed maximum up to 27 months
Objective Response Rate (ORR) in the ATM Negative Patients
Objective response rate is the proportion of ATM negative patients with at least one measurable lesion at baseline, who experienced complete or partial response at least once during the assessment period, according to the definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1).
Time frame: Tumour assessments carried out at baseline, 28 days before randomisation then every 8 weeks until week 40, after week 40 assessments will be carried out every 16 weeks until objective disease progression, assessed maximum up to 27 months
Percentage Change in Tumour Size at Week 8 in the Overall Study Population
Percentage change in tumour size from baseline to Week 8 calculated as 100 X (week 8 tumour size - baseline tumour size) / (baseline tumour size)
Time frame: Tumour scans done at Baseline and week 8
Percentage Change in Tumour Size at Week 8 in the ATM Negative Patients
Percentage change in tumour size from baseline to Week 8 calculated as 100 X (week 8 tumour size - baseline tumour size) / (baseline tumour size)
Time frame: Tumour scans done at Baseline and week 8
Time to Deterioration in Global Quality of Life (QoL) Score in the Overall Study Population
Time calculated from randomisation till worsening of Global QoL score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data
Time frame: Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months
Time to Deterioration in QoL Fatigue Score in the Overall Study Population
Time calculated from randomisation till worsening of fatigue score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data
Time frame: Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months
Time to Deterioration in QoL Nausea & Vomiting Domain Score in the Overall Study Population
Time calculated from randomisation till worsening of nausea \& vomiting domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data
Time frame: Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months
Time to Deterioration in QoL Pain Domain Score in the Overall Study Population
Time calculated from randomisation till worsening of pain domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data
Time frame: Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months
Time to Deterioration in QoL Dysphagia Domain Score in the Overall Study Population
Time calculated from randomisation till worsening of dysphagia domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data
Time frame: Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months
Time to Deterioration in QoL Eating Restriction Domain Score in the Overall Study Population
Time calculated from randomisation till worsening of eating restriction domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data
Time frame: Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months
Time to Deterioration in QoL Stomach Pain Domain Score in the Overall Study Population
Time calculated from randomisation till worsening of stomach pain domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data
Time frame: Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months
Time to Deterioration in QoL Reflux Domain Score in the Overall Study Population
Time calculated from randomisation till worsening of reflux domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data
Time frame: Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months
Time to Deterioration in QoL Anxiety Domain Score in the Overall Study Population
Time calculated from randomisation till worsening of anxiety domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data
Time frame: Questionnaire data collected at Baseline ie on or before date of randomisation, every 4 weeks post baseline, assessed maximum up to 27 months
This study was conducted at 13 sites in South Korea. Enrolment started in February 2010 and was completed in May 2012. In total 124 patients were randomised in the study (62 in the olaparib+paclitaxel arm and 62 in the placebo+paclitaxel arm).
| Milestone | Olaparib+Paclitaxel | Placebo+Paclitaxel |
|---|---|---|
| Started | 62 | 62 |
| Received randomised treatment | 61 | 62 |
| Completed | 4 | 2 |
| Not completed | 58 | 60 |
| Withdrew: Consent withdrawal | 1 | 0 |
| Withdrew: Study reached data cut-off | 19 | 7 |
| Withdrew: Lost to follow-up | 4 | 3 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Death | 33 | 48 |
PFS is defined as the time from randomisation till objective progression or death. In absence of progression or death, the time is calculated from randomisation till last evaluable scanning visit.
| months | Olaparib+Paclitaxel | Placebo+Paclitaxel |
|---|---|---|
| Progression Free Survival (PFS) in the Overall Study Population | 3.91 (3.02 to 7.13) | 3.55 (1.74 to 5.82) |
PFS is defined as the time from randomisation till objective progression or death. In absence of progression or death, the time is calculated from randomisation till last evaluable scanning visit.
| months | Olaparib+Paclitaxel | Placebo+Paclitaxel |
|---|---|---|
| Progression Free Survival (PFS) in Patients With Tumours Defined as Homologous Recombination Deficient by Loss of Ataxia-Telangiectasia Mutation (ATM) Protein [ATM Negative Patients] | 5.29 (3.38 to 5.72) | 3.68 (1.77 to 5.82) |
Overall survival is defined as the duration from randomisation till death. In absence of death, the time is calculated from randomisation till the date subject last known to be alive.
| months | Olaparib+Paclitaxel | Placebo+Paclitaxel |
|---|---|---|
| Overall Survival (OS) in the Overall Study Population | 13.1 (7.10 to NA) | 8.3 (5.30 to 14.90) |
Overall survival is defined as the duration from randomisation till death. In absence of death, the time is calculated from randomisation till the date subject last known to be alive.
| months | Olaparib+Paclitaxel | Placebo+Paclitaxel |
|---|---|---|
| Overall Survival (OS) in ATM Negative Patients | NA (9.30 to NA) | 8.20 (5.10 to 13.10) |
Objective response rate is the proportion of patients with at least one measurable lesion at baseline, who experienced complete or partial response at least once during the assessment period, according to the definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1).
| Participants | Olaparib+Paclitaxel | Placebo+Paclitaxel |
|---|---|---|
| Objective Response Rate (ORR) in the Overall Study Population | 14 | 9 |
Objective response rate is the proportion of ATM negative patients with at least one measurable lesion at baseline, who experienced complete or partial response at least once during the assessment period, according to the definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1).
| Participants | Olaparib+Paclitaxel | Placebo+Paclitaxel |
|---|---|---|
| Objective Response Rate (ORR) in the ATM Negative Patients | 9 | 6 |
Percentage change in tumour size from baseline to Week 8 calculated as 100 X (week 8 tumour size - baseline tumour size) / (baseline tumour size)
| Percent change | Olaparib+Paclitaxel | Placebo+Paclitaxel |
|---|---|---|
| Percentage Change in Tumour Size at Week 8 in the Overall Study Population | -5.8 ± 29.09 | 2.2 ± 35.6 |
Percentage change in tumour size from baseline to Week 8 calculated as 100 X (week 8 tumour size - baseline tumour size) / (baseline tumour size)
| Percent change | Olaparib+Paclitaxel | Placebo+Paclitaxel |
|---|---|---|
| Percentage Change in Tumour Size at Week 8 in the ATM Negative Patients | -6.9 ± 29.31 | -5.9 ± 26.36 |
Time calculated from randomisation till worsening of Global QoL score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data
| months | Olaparib+Paclitaxel | Placebo+Paclitaxel |
|---|---|---|
| Time to Deterioration in Global Quality of Life (QoL) Score in the Overall Study Population | 3.6 ± 29.31 | 2.8 ± 26.36 |
Time calculated from randomisation till worsening of fatigue score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data
| months | Olaparib+Paclitaxel | Placebo+Paclitaxel |
|---|---|---|
| Time to Deterioration in QoL Fatigue Score in the Overall Study Population | 1.9 ± 29.31 | 1.8 ± 26.36 |
Time calculated from randomisation till worsening of nausea \& vomiting domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data
| months | Olaparib+Paclitaxel | Placebo+Paclitaxel |
|---|---|---|
| Time to Deterioration in QoL Nausea & Vomiting Domain Score in the Overall Study Population | 3.7 ± 29.31 | 3.7 ± 26.36 |
Time calculated from randomisation till worsening of pain domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data
| months | Olaparib+Paclitaxel | Placebo+Paclitaxel |
|---|---|---|
| Time to Deterioration in QoL Pain Domain Score in the Overall Study Population | 3.2 ± 29.31 | 3.1 ± 26.36 |
Time calculated from randomisation till worsening of dysphagia domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data
| months | Olaparib+Paclitaxel | Placebo+Paclitaxel |
|---|---|---|
| Time to Deterioration in QoL Dysphagia Domain Score in the Overall Study Population | 3.7 ± 29.31 | 1.9 ± 26.36 |
Time calculated from randomisation till worsening of eating restriction domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data
| months | Olaparib+Paclitaxel | Placebo+Paclitaxel |
|---|---|---|
| Time to Deterioration in QoL Eating Restriction Domain Score in the Overall Study Population | 4.6 ± 29.31 | 5.1 ± 26.36 |
Time calculated from randomisation till worsening of stomach pain domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data
| months | Olaparib+Paclitaxel | Placebo+Paclitaxel |
|---|---|---|
| Time to Deterioration in QoL Stomach Pain Domain Score in the Overall Study Population | 6.9 ± 29.31 | 5.7 ± 26.36 |
Time calculated from randomisation till worsening of reflux domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data
| months | Olaparib+Paclitaxel | Placebo+Paclitaxel |
|---|---|---|
| Time to Deterioration in QoL Reflux Domain Score in the Overall Study Population | 4.3 ± 29.31 | 2.8 ± 26.36 |
Time calculated from randomisation till worsening of anxiety domain score based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaire data
| months | Olaparib+Paclitaxel | Placebo+Paclitaxel |
|---|---|---|
| Time to Deterioration in QoL Anxiety Domain Score in the Overall Study Population | 2.8 ± 29.31 | 1.9 ± 26.36 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OLAPARIB 100MG BD + PACLITAXEL / OLAPARIB 200MG BD | — | 17/61 (27.9%) | 61/61 (100%) |
| PLACEBO 100MG BD + PACLITAXEL / PLACEBO 200MG BD | — | 23/62 (37.1%) | 62/62 (100%) |
| Event | OLAPARIB 100MG BD + PACLITAXEL / OLAPARIB 200MG BD | PLACEBO 100MG BD + PACLITAXEL / PLACEBO 200MG BD |
|---|---|---|
| PNEUMONIAInfections and infestations | 3/61 | 6/62 |
| FATIGUEGeneral disorders | 2/61 | 2/62 |
| ASTHENIAGeneral disorders | 1/61 | 2/62 |
| PAINGeneral disorders | 0/61 | 2/62 |
| PYREXIAGeneral disorders | 1/61 | 2/62 |
| ENTEROCOLITIS INFECTIOUSInfections and infestations | 0/61 | 2/62 |
| DECREASED APPETITEMetabolism and nutrition disorders | 1/61 | 2/62 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 1/61 | 0/62 |
| NEUTROPENIABlood and lymphatic system disorders | 1/61 | 1/62 |
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 1/61 | 0/62 |
| Event | OLAPARIB 100MG BD + PACLITAXEL / OLAPARIB 200MG BD | PLACEBO 100MG BD + PACLITAXEL / PLACEBO 200MG BD |
|---|---|---|
| NEUTROPENIABlood and lymphatic system disorders | 46/61 | 40/62 |
| ALOPECIASkin and subcutaneous tissue disorders | 30/61 | 29/62 |
| NAUSEAGastrointestinal disorders | 21/61 | 26/62 |
| DECREASED APPETITEMetabolism and nutrition disorders | 23/61 | 25/62 |
| NEUROPATHY PERIPHERALNervous system disorders | 22/61 | 13/62 |
| MYALGIAMusculoskeletal and connective tissue disorders | 10/61 | 22/62 |
| DIARRHOEAGastrointestinal disorders | 20/61 | 17/62 |
| ASTHENIAGeneral disorders | 19/61 | 15/62 |
| FATIGUEGeneral disorders | 15/61 | 19/62 |
| ABDOMINAL PAINGastrointestinal disorders | 15/61 | 16/62 |
| Age, Continuous(years) | Olaparib+Paclitaxel | Placebo+Paclitaxel | Total |
|---|---|---|---|
| Mean | 59.0 ± 11.61 | 59.4 ± 11.98 | 59.2 ± 11.75 |
| Age, Customized(Participants) | Olaparib+Paclitaxel | Placebo+Paclitaxel | Total |
|---|---|---|---|
| < 50 years | 13 | 10 | 23 |
| >=50 to <65 years | 22 | 30 | 52 |
| >= 65 years | 27 | 22 | 49 |
| Sex: Female, Male(Participants) | Olaparib+Paclitaxel | Placebo+Paclitaxel | Total |
|---|---|---|---|
| Female | 13 | 18 | 31 |
| Male | 49 | 44 | 93 |
| Race/Ethnicity, Customized(Participants) | Olaparib+Paclitaxel | Placebo+Paclitaxel | Total |
|---|---|---|---|
| Asian | 62 | 62 | 124 |
| Other | 0 | 0 | 0 |
| ATM status(Participants) | Olaparib+Paclitaxel | Placebo+Paclitaxel | Total |
|---|---|---|---|
| Negative | 31 | 32 | 63 |
| Positive | 31 | 30 | 61 |
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Feb 2010 to primary completion in May 2012, 27 months.
Results were first posted in Apr 2015, 2 years 11 months after primary completion. A results delay was requested in Jul 2013.
Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's 27 months is below that.
Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib